Blood Culture Test Market (By Product: Consumables, Instruments; By Technique: Conventional, Automated; By Application; By Technology) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

The global blood culture test market was valued at USD 6.71 billion in 2023 and it is predicted to surpass around USD 21.47 billion by 2033 with a CAGR of 12.34% from 2024 to 2033.

Blood Culture Test Market Size 2024 to 2033

Key Pointers

  • North America led the market with the largest market share of 41% in 2023.
  • Asia Pacific is poised to witness the highest CAGR during the forecast period.
  • By Product, the consumables segment held the largest revenue share of 60% in 2023 and is projected to experience the fastest CAGR between 2024 to 2033.
  • By Technique, the conventional blood culture technique segment contributed the largest market share of 65% in 2023.
  • By Technology, the culture-based technology segment had the largest market share of 68% in 2023.
  • By Application, the bacterial infections segment held the largest revenue share of 72% in 2022 and is projected to experience the highest CAGR from 2024 to 2033.
  • By End-use, the hospital laboratories segment accounted for the largest share of 55% in 2023.

Blood Culture Test Market Overview

The blood culture test market plays a pivotal role in the diagnosis and management of various infectious diseases. This comprehensive overview delves into the key factors influencing the market, including current trends, growth drivers, challenges, and opportunities. Understanding the dynamics of the blood culture test market is essential for stakeholders, healthcare professionals, and investors aiming to navigate this evolving landscape.

Blood Culture Test Market Growth

The growth of the blood culture test market is propelled by various factors contributing to its expanding significance in the healthcare sector. Firstly, the rising global incidence of infectious diseases, particularly sepsis and hospital-acquired infections, has significantly increased the demand for accurate and timely diagnostic solutions, driving the market's expansion. Additionally, continual technological advancements play a pivotal role, with innovations such as automated blood culture systems and molecular diagnostics enhancing the efficiency and precision of diagnostic procedures. The incorporation of these advanced technologies not only reduces turnaround times but also contributes to improved patient outcomes. Moreover, the market is buoyed by the strategic initiatives of key players, who constantly strive to expand their product portfolios and geographic reach.

Report Scope of the Blood Culture Test Market

Report Coverage Details
Growth Rate from 2024 to 2033 CAGR of 12.34%
Market Revenue by 2032 USD 21.47 billion
Revenue Share of North America in 2023 41%
Base Year 2023
Forecast Period 2024 to 2033
Market Analysis (Terms Used) Value (US$ Million/Billion) or (Volume/Units)

 

Blood Culture Test Market Dynamics

Drivers

  • Increasing Prevalence of Infectious Diseases: The surge in global infectious disease cases, particularly instances of sepsis and hospital-acquired infections, is a primary driver for the growth of the blood culture test market. The necessity for accurate and prompt diagnosis in managing these conditions has led to a growing demand for blood culture tests.
  • Demand for Timely Diagnosis: The urgency in diagnosing infectious diseases, especially in critical conditions like sepsis, fuels the demand for blood culture tests. The ability of these tests to provide quick and accurate results is crucial for initiating timely and appropriate treatment, thereby improving patient outcomes.

Restraints

  • High Cost of Advanced Diagnostic Technologies: One significant restraint facing the blood culture test market is the high cost associated with advanced diagnostic technologies. The implementation of automated blood culture systems and molecular diagnostics often requires substantial investment, posing a financial challenge for healthcare facilities, particularly in resource-constrained settings.
  • Limited Accessibility and Affordability: Despite technological advancements, there are disparities in the accessibility and affordability of blood culture tests, particularly in developing regions. The high costs associated with these tests, coupled with limited healthcare infrastructure, hinder widespread adoption, leading to unequal access to advanced diagnostic capabilities.

Opportunities

  • Rising Emphasis on Point-of-Care Testing: The increasing emphasis on point-of-care testing presents a significant opportunity in the blood culture test market. The development of rapid and portable blood culture testing devices can address the need for quicker diagnostics, especially in settings where immediate results are crucial for effective patient management.
  • Expanding Application in Veterinary Medicine: The application of blood culture tests in veterinary medicine represents an untapped opportunity for market growth. As awareness of infectious diseases in animals grows, there is an increasing need for accurate diagnostic tools, opening avenues for blood culture tests in the veterinary healthcare sector.

Product Insights

The consumables segment held the largest revenue share of 60% in 2023 and is projected to experience the fastest CAGR throughout the forecast period. The dominant market position can be attributed to the increasing number of blood culture tests, a rising incidence of infectious diseases, and a growing awareness of the procedure's benefits. Technological advancements and continuous improvements in existing products are expected to create a conducive environment for the growth of this segment. For instance, in February 2022, Kurin, Inc. introduced its proprietary push-button needle system, showcasing a commitment to advanced safety measures.

Software systems have been developed to mitigate false positives during the blood culture test process, aiming to prevent incorrect diagnoses. An inaccurate diagnosis not only significantly escalates healthcare costs but may also lead to fatalities due to the administration of wrongly prescribed medications. Moreover, these software systems play a crucial role in determining the degree of relatedness between various analyzed strains, offering highly reproducible and discriminatory data.

Technique Insights

The market is categorized based on techniques into conventional and automated segments. In 2023, the conventional blood culture technique segment contributed the largest market share of 65%. This dominance can be attributed to its widespread utilization in hospitals, pathology laboratories, and clinical laboratories. Additionally, the segment is poised for growth due to the increasing focus on research and development activities aimed at enhancing the efficiency of blood culture tests. A notable example is the collaborative research conducted by the Great Ormond Street Institute of Child Health (GOSH) and Wyss Institute for Biologically in December 2022, which reported successful results in reengineered procedures for identifying pathogens associated with pediatric sepsis.

On the other hand, the automated blood culture technique segment is expected to exhibit the fastest growth rate during the forecast period. Key companies in the market are keenly concentrating on introducing advanced instruments and consumables to offer highly efficient and reliable tests. In January 2022, QIAGEN launched the EZ2 Connect MDx platform, designed to automate sample processing in diagnostic labs, thereby enhancing overall process efficiency. This emphasis on automation aligns with the growing demand for streamlined and technologically advanced blood culture testing methods.

Technology Insights

The culture-based technology segment had the largest market share of 68% in 2023. This dominance is attributed to the heightened capabilities of this technology in detecting pathogens effectively. The increasing prevalence of infectious diseases and rising research and development investments in developing countries are anticipated to further propel the growth of this segment. The widespread use of culture-based technology across various end-use locations, including hospitals, physician office laboratories, reference, and pathology settings, is also expected to be a driving factor for its continued growth.

In contrast, the molecular technology segment is poised to register the highest CAGR during the forecast period. Molecular technologies, encompassing blood cultures and nucleic acid amplification & probe tests, have notably enhanced the precision and speed of results, reducing turnaround times in Bloodstream Infections (BSIs). Innovative approaches for rapid BSI diagnosis, such as automated Antibiotic Susceptibility Testing (AST) from positive blood culture bottles by Accelerate Diagnostics and direct pathogen detection from peripheral blood by T2 Biosystems, boast an expected turnaround time of less than 6 hours. The approval of these tests is anticipated to yield more informative, cost-effective, and expeditious results, contributing significantly to BSI management.

Application Insights

The bacterial infections segment held the largest revenue share of 72% in 2023 and is projected to experience the highest CAGR throughout the forecast period. This dominance is primarily attributed to the escalating global incidence of bacterial infections. The strategic collaborations among market players aimed at introducing new products and technologies are anticipated to further accelerate the growth of this segment. A noteworthy example is the partnership forged in April 2022 between bioMerieux and Oxford Nanopore Technologies plc. This collaboration aims to develop faster, more accurate, and user-friendly blood culture tests, enhancing the diagnosis and treatment of infectious diseases.

In contrast, the fungal infections segment is poised to witness significant growth in the upcoming years. This growth is driven by the prevalence of Bloodstream Infections (BSIs) and the increasing number of sepsis cases on a global scale. Candida species, in particular, stand out as predominant agents of fungal sepsis, constituting approximately 10% to 15% of healthcare-related infections.

End-use Insights

The hospital laboratories segment accounted for the largest share of 55% in 2023 owing to an increasing rate of hospitalizations and growing cases of Hospital-acquired Infections (HAIs). According to an article published by WHO in 2022, 7 patients and 15 patients out of every 100 patients in an acute-care hospital setting in high-income and low & middle-income countries respectively, will acquire at least one HAI at the time of their stay in hospital. Typically, in such settings, prompt detection allows the physicians to plan a proper treatment regimen for the patient. In underdeveloped and developing countries, which lack access to rapid diagnostic tests, hospitals serve as primary testing facilities.

Blood Culture Test Market Share, By End-use, 2023 (%)

The reference laboratory segment is anticipated to witness the fastest CAGR during the forecast period. Reference laboratories are often listed by insurance companies for specific tests, requiring patients to provide samples for testing. With an increase in incidence of infectious diseases, volume of blood culture tests has also increased causing a spur in the growth of reference laboratories segment.These laboratories operate privately and are engaged in a high volume of routine and specialty testing. These facilities have several advantages, such as they provide fast results (approximately 3–4 hours); are highly sensitive, specific, scalable, & cost-efficient; and facilitate the testing of many sample types.

Regional Insights

North America dominated the market with the largest market share of 41% in 2023. This leadership position is attributed to a well-established clinical diagnostics industry, the presence of numerous key players, government-funded programs, a structured reimbursement framework, awareness initiatives, and frequent new product launches. Notably, in February 2022, the Biomedical Advanced Research and Development Authority (BARDA) received FDA Approval for the Selux NGP System, developed in collaboration with Selux Diagnostics, Inc. This system facilitates testing directly from positive blood cultures, effectively reducing the total test time from 36 hours to 16 hours from whole blood collection.

Blood Culture Test Market Share, By Region, 2023 (%)

On the other hand, Asia Pacific is poised to witness the highest CAGR during the forecast period. This growth is driven by an increase in hospitalizations and a rise in the incidence of various diseases such as urinary tract infections, bloodstream infections, and ventilator-associated pneumonia. Key market players are strategically expanding their presence into Asian countries like China and India due to high unmet needs, abundant opportunities for market share growth, and the presence of the target population. The region's dynamic healthcare landscape and evolving market conditions contribute to the anticipated rapid growth in blood culture tests in Asia Pacific.

Key Companies

  • BD
  • Terumo Corporation
  • Bruker Corporation
  • bioMerieux
  • T2 Biosystems Inc.
  • Luminex Corporation
  • Abbott Laboratories
  • Siemens Healthineers AG
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.

Blood Culture Test Market Segmentations:

By Product

  • Consumables
    • By Type
      • Bacterial Infections
      • Fungal Infections
      • Mycobacterial Infections
    • By Components
      • Blood Culture Media
        • Aerobic
        • Anaerobic
        • Fungi/Yeast
        • Others
      • Assay, Kits, and Reagents
      • Blood Culture Accessories
  • Instruments
    • By Type
      • Bacterial Infections
      • Fungal Infections
      • Mycobacterial Infections
    • By Components
      • Laboratory Equipment
        • Incubators
        • Colony Counters
        • Microscopes
        • Gram Stainers
      • Automated Blood Culture Systems
  • Software & Services
    • Bacterial Infections
    • Fungal Infections
    • Mycobacterial Infections

By Technique

  • Conventional
  • Automated

By Technology

  • Culture-based Technology
  • Molecular Technology
    • PCR
    • Microarray
    • PNA-FISH
  • Proteomic Technology

By Application

  • Bacterial Infections
  • Fungal Infections
  • Mycobacterial Infections

By End-use

  • Hospital Laboratories
  • Reference Laboratories
  • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • MEA

Frequently Asked Questions

The global blood culture test market size was reached at USD 6.71 billion in 2023 and it is projected to hit around USD 21.47 billion by 2033.

The global blood culture test market is growing at a compound annual growth rate (CAGR) of 12.34% from 2024 to 2033.

The North America region has accounted for the largest blood culture test market share in 2023.

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Blood Culture Test Market 

5.1. COVID-19 Landscape: Blood Culture Test Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Blood Culture Test Market, By Product

8.1. Blood Culture Test Market, by Product, 2024-2033

8.1.1. Consumables

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Instruments

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Software & Services

8.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Blood Culture Test Market, By Technique

9.1. Blood Culture Test Market, by Technique, 2024-2033

9.1.1. Conventional

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Automated

9.1.2.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Blood Culture Test Market, By Technology 

10.1. Blood Culture Test Market, by Technology, 2024-2033

10.1.1. Culture-based Technology

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Molecular Technology

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. PCR

10.1.3.1. Market Revenue and Forecast (2021-2033)

10.1.4. Microarray

10.1.4.1. Market Revenue and Forecast (2021-2033)

10.1.5. PNA-FISH

10.1.5.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Blood Culture Test Market, By Application

11.1. Blood Culture Test Market, by Application, 2024-2033

11.1.1. Bacterial Infections

11.1.1.1. Market Revenue and Forecast (2021-2033)

11.1.2. Fungal Infections

11.1.2.1. Market Revenue and Forecast (2021-2033)

11.1.3. Mycobacterial Infections

11.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 12. Global Blood Culture Test Market, By End-use

12.1. Blood Culture Test Market, by End-use, 2024-2033

12.1.1. Hospital Laboratories

12.1.1.1. Market Revenue and Forecast (2021-2033)

12.1.2. Reference Laboratories

12.1.2.1. Market Revenue and Forecast (2021-2033)

12.1.3. Others

12.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 13. Global Blood Culture Test Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Product (2021-2033)

13.1.2. Market Revenue and Forecast, by Technique (2021-2033)

13.1.3. Market Revenue and Forecast, by Technology (2021-2033)

13.1.4. Market Revenue and Forecast, by Application (2021-2033)

13.1.5. Market Revenue and Forecast, by End-use (2021-2033)

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Product (2021-2033)

13.1.6.2. Market Revenue and Forecast, by Technique (2021-2033)

13.1.6.3. Market Revenue and Forecast, by Technology (2021-2033)

13.1.6.4. Market Revenue and Forecast, by Application (2021-2033)

13.1.7. Market Revenue and Forecast, by End-use (2021-2033) 

13.1.8. Rest of North America

13.1.8.1. Market Revenue and Forecast, by Product (2021-2033)

13.1.8.2. Market Revenue and Forecast, by Technique (2021-2033)

13.1.8.3. Market Revenue and Forecast, by Technology (2021-2033)

13.1.8.4. Market Revenue and Forecast, by Application (2021-2033)

13.1.8.5. Market Revenue and Forecast, by End-use (2021-2033)

13.2. Europe

13.2.1. Market Revenue and Forecast, by Product (2021-2033)

13.2.2. Market Revenue and Forecast, by Technique (2021-2033)

13.2.3. Market Revenue and Forecast, by Technology (2021-2033)

13.2.4. Market Revenue and Forecast, by Application (2021-2033) 

13.2.5. Market Revenue and Forecast, by End-use (2021-2033) 

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Product (2021-2033)

13.2.6.2. Market Revenue and Forecast, by Technique (2021-2033)

13.2.6.3. Market Revenue and Forecast, by Technology (2021-2033)

13.2.7. Market Revenue and Forecast, by Application (2021-2033) 

13.2.8. Market Revenue and Forecast, by End-use (2021-2033) 

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Product (2021-2033)

13.2.9.2. Market Revenue and Forecast, by Technique (2021-2033)

13.2.9.3. Market Revenue and Forecast, by Technology (2021-2033)

13.2.10. Market Revenue and Forecast, by Application (2021-2033)

13.2.11. Market Revenue and Forecast, by End-use (2021-2033)

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Product (2021-2033)

13.2.12.2. Market Revenue and Forecast, by Technique (2021-2033)

13.2.12.3. Market Revenue and Forecast, by Technology (2021-2033)

13.2.12.4. Market Revenue and Forecast, by Application (2021-2033)

13.2.13. Market Revenue and Forecast, by End-use (2021-2033)

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Product (2021-2033)

13.2.14.2. Market Revenue and Forecast, by Technique (2021-2033)

13.2.14.3. Market Revenue and Forecast, by Technology (2021-2033)

13.2.14.4. Market Revenue and Forecast, by Application (2021-2033)

13.2.15. Market Revenue and Forecast, by End-use (2021-2033)

13.3. APAC

13.3.1. Market Revenue and Forecast, by Product (2021-2033)

13.3.2. Market Revenue and Forecast, by Technique (2021-2033)

13.3.3. Market Revenue and Forecast, by Technology (2021-2033)

13.3.4. Market Revenue and Forecast, by Application (2021-2033)

13.3.5. Market Revenue and Forecast, by End-use (2021-2033)

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Product (2021-2033)

13.3.6.2. Market Revenue and Forecast, by Technique (2021-2033)

13.3.6.3. Market Revenue and Forecast, by Technology (2021-2033)

13.3.6.4. Market Revenue and Forecast, by Application (2021-2033)

13.3.7. Market Revenue and Forecast, by End-use (2021-2033)

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Product (2021-2033)

13.3.8.2. Market Revenue and Forecast, by Technique (2021-2033)

13.3.8.3. Market Revenue and Forecast, by Technology (2021-2033)

13.3.8.4. Market Revenue and Forecast, by Application (2021-2033)

13.3.9. Market Revenue and Forecast, by End-use (2021-2033)

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Product (2021-2033)

13.3.10.2. Market Revenue and Forecast, by Technique (2021-2033)

13.3.10.3. Market Revenue and Forecast, by Technology (2021-2033)

13.3.10.4. Market Revenue and Forecast, by Application (2021-2033)

13.3.10.5. Market Revenue and Forecast, by End-use (2021-2033)

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Product (2021-2033)

13.3.11.2. Market Revenue and Forecast, by Technique (2021-2033)

13.3.11.3. Market Revenue and Forecast, by Technology (2021-2033)

13.3.11.4. Market Revenue and Forecast, by Application (2021-2033)

13.3.11.5. Market Revenue and Forecast, by End-use (2021-2033)

13.4. MEA

13.4.1. Market Revenue and Forecast, by Product (2021-2033)

13.4.2. Market Revenue and Forecast, by Technique (2021-2033)

13.4.3. Market Revenue and Forecast, by Technology (2021-2033)

13.4.4. Market Revenue and Forecast, by Application (2021-2033)

13.4.5. Market Revenue and Forecast, by End-use (2021-2033)

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Product (2021-2033)

13.4.6.2. Market Revenue and Forecast, by Technique (2021-2033)

13.4.6.3. Market Revenue and Forecast, by Technology (2021-2033)

13.4.6.4. Market Revenue and Forecast, by Application (2021-2033)

13.4.7. Market Revenue and Forecast, by End-use (2021-2033)

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Product (2021-2033)

13.4.8.2. Market Revenue and Forecast, by Technique (2021-2033)

13.4.8.3. Market Revenue and Forecast, by Technology (2021-2033)

13.4.8.4. Market Revenue and Forecast, by Application (2021-2033)

13.4.9. Market Revenue and Forecast, by End-use (2021-2033)

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Product (2021-2033)

13.4.10.2. Market Revenue and Forecast, by Technique (2021-2033)

13.4.10.3. Market Revenue and Forecast, by Technology (2021-2033)

13.4.10.4. Market Revenue and Forecast, by Application (2021-2033)

13.4.10.5. Market Revenue and Forecast, by End-use (2021-2033)

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Product (2021-2033)

13.4.11.2. Market Revenue and Forecast, by Technique (2021-2033)

13.4.11.3. Market Revenue and Forecast, by Technology (2021-2033)

13.4.11.4. Market Revenue and Forecast, by Application (2021-2033)

13.4.11.5. Market Revenue and Forecast, by End-use (2021-2033)

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Product (2021-2033)

13.5.2. Market Revenue and Forecast, by Technique (2021-2033)

13.5.3. Market Revenue and Forecast, by Technology (2021-2033)

13.5.4. Market Revenue and Forecast, by Application (2021-2033)

13.5.5. Market Revenue and Forecast, by End-use (2021-2033)

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Product (2021-2033)

13.5.6.2. Market Revenue and Forecast, by Technique (2021-2033)

13.5.6.3. Market Revenue and Forecast, by Technology (2021-2033)

13.5.6.4. Market Revenue and Forecast, by Application (2021-2033)

13.5.7. Market Revenue and Forecast, by End-use (2021-2033)

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Product (2021-2033)

13.5.8.2. Market Revenue and Forecast, by Technique (2021-2033)

13.5.8.3. Market Revenue and Forecast, by Technology (2021-2033)

13.5.8.4. Market Revenue and Forecast, by Application (2021-2033)

13.5.8.5. Market Revenue and Forecast, by End-use (2021-2033)

Chapter 14. Company Profiles

14.1. BD

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Terumo Corporation

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Bruker Corporation

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. bioMerieux

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. T2 Biosystems Inc.

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Luminex Corporation

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Abbott Laboratories

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Siemens Healthineers AG

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Danaher Corporation

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. F. Hoffmann-La Roche Ltd.

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers